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a b s t r a c t 
Background: Estimates of the burden of cardio-metabolic risk factors in Latin America and the Caribbean 
(LAC) rely on relative risks (RRs) from non-LAC countries. Whether these RRs apply to LAC remains un- 
known. 
Methods: We pooled LAC cohorts. We estimated RRs per unit of exposure to body mass index (BMI), 
systolic blood pressure (SBP), fasting plasma glucose (FPG), total cholesterol (TC) and non-HDL cholesterol 
on fatal (31 cohorts, n = 168,287) and non-fatal (13 cohorts, n = 27,554) cardiovascular diseases, adjusting 
for regression dilution bias. We used these RRs and national data on mean risk factor levels to estimate 
the number of cardiovascular deaths attributable to non-optimal levels of each risk factor. 
Results: Our RRs for SBP, FPG and TC were like those observed in cohorts conducted in high-income 
countries; however, for BMI, our RRs were consistently smaller in people below 75 years of age. Across 
risk factors, we observed smaller RRs among older ages. Non-optimal SBP was responsible for the largest 
number of attributable cardiovascular deaths ranging from 38 per 10 0,0 0 0 women and 54 men in Peru, 
to 261 (Dominica, women) and 282 (Guyana, men). For non-HDL cholesterol, the lowest attributable rate 
was for women in Peru (21) and men in Guatemala (25), and the largest in men (158) and women (142) 
from Guyana. 
Interpretation: RRs for BMI from studies conducted in high-income countries may overestimate disease 
burden metrics in LAC; conversely, RRs for SBP, FPG and TC from LAC cohorts are similar to those esti- 
mated from cohorts in high-income countries. 
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Research In Context 
Evidence before this study 
The search query ("Latin America" AND "Caribbean") 
AND ("relative risks" OR "population attributable fraction 
OR "PAF") AND ("body mass index" OR "BMI" OR "blood 
pressure" OR "total cholesterol" OR "fasting glucose") did 
not retrieve any results in PubMed (June 14 th 2021). It is 
well known that Latin America and the Caribbean has not 
had large multi-country cohort studies or cohort pooling ∗ Corresponding Author: Dr. Goodarz Danaei, Harvard T.H. Chan School of Public 
ealth, Department of Epidemiology, 677 Huntington Avenue, Building 1, 11th Floor, 
oom 1107, Boston, MA 02115, United States, Phone: + 16174325722 
E-mail address: gdanaei@hsph.harvard.edu (Cohorts Consortium of Latin Amer- 
ca and the Caribbean (CC-LAC)) 
1 Authors listed at end. 
ttps://doi.org/10.1016/j.lana.2021.10 0 068 
667-193X/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access articleprojects. Before this work, the evidence about long-terms ef- 
fects of cardio-metabolic risk factors in Latin America and 
the Caribbean was informed by cohorts conducted in North 
America, Europe and Asia. 
Added value of this study 
This work pooled data from several Latin American and 
the Caribbean cohorts and examined the relative risks of es- 
tablished cardio-metabolic risk factors for cardiovascular out- 
comes. We found that the relative risks for systolic blood 
pressure, fasting glucose and total cholesterol, are similar 
to those reported by cohort pooling projects carried out in 
other world regions (e.g., Asia-Pacific Cohort Studies Collab- 
oration, Prospective Studies Collaboration and Emerging Risk 
Factors Collaboration); however, for body mass index, the rel- 
ative risks were slightly smaller in Latin America and the 
Caribbean. We used the relative risks herein derived to es- 
timate the mortality attributable to non-optimal levels of  under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) 






























































































t  the selected cardio-metabolic risk factors. We estimated the 
largest attributable cardiovascular deaths due to non-optimal 
systolic blood pressure and non-HDL cholesterol. These risk 
factors had a larger impact on cardiovascular deaths in the 
Caribbean, as well as in Southern and Tropical sub-regions. 
Implications for all the available evidence 
Our results support using global relative risks for systolic 
blood pressure, fasting glucose and total cholesterol in Latin 
America and the Caribbean; for body mass index, however, it 
seems reasonable to use the relative risks herein proposed. 
Global relative risks for body mass index may overestimate 
disease burden metrics in Latin America and the Caribbean. 
. Introduction 
Cardiovascular diseases are the leading causes of death glob- 
lly [1] , and the main causes of these deaths are a set of well-
nown cardio-metabolic risk factors such as high blood pressure, 
verweight/obesity, diabetes and dyslipidemias [2-4] . Supporting 
vidence on the impact of cardio-metabolic risk factors on cardio- 
ascular diseases has mostly come from cohort pooling collabo- 
ations [5] , including the Asia-Pacific Cohort Studies Collaboration 
 6 , 7 ], the Prospective Studies Collaboration [8-10] , and the Emerg-
ng Risk Factors Collaboration [11-13] . The results of these collab- 
rations have been used to attribute disease burden to risk fac- 
ors globally, providing inputs for surveillance and monitoring of 
ardio-metabolic risk factors and diseases. 
These collaborations have little representation from Latin Amer- 
ca and the Caribbean (LAC) [14] , a vast region with unique char- 
cteristics in terms of non-communicable diseases such as diabetes 
nd raised blood pressure [15] , paired with the fastest rate of tran- 
ition towards a predominance of urban areas in the developing 
orld [ 16 , 17 ]. Therefore, the findings of these non-LAC collabora- 
ions, such as the age-specific relative risks used in global bur- 
en of disease estimations, may not apply to LAC countries. In 
act, evidence suggests that the association between some risk fac- 
ors and cardio-metabolic outcomes may be stronger in LAC com- 
ared with other world regions [ 4 , 18 ], possibly due to different lev-
ls of access to health care [ 19 , 20 ], differences in the distribution
f cardio-metabolic risk factors [ 15 , 21-23 ], or incidence of non- 
ommunicable diseases [24-26] . We identified and pooled prospec- 
ive cohort studies in LAC to examine the effect of major cardio- 
etabolic risk factors on cardiovascular outcomes, and to estimate 
ge-specific relative risks for this world region. 
. Methods 
Details about the Cohorts Consortium of Latin America and the 
aribbean (CC-LAC) have been reported detailed elsewhere [27] . 
e analysed cohort data pooled and harmonized by the CC-LAC 
27] , a network of health researchers and practitioners in LAC. 
e have harmonised and pooled approximately population-based 
ohort data on cardio-metabolic risk factors and outcomes, i.e., 
articipants were not recruited based on cardiovascular diseases 
CVD) (e.g., cohort of stroke survivors) or risk factor (e.g., cohort 
f smokers) history only. Cohort studies were identified through a 
ystematic search and networks of researchers in LAC. We identi- 
ed 78 approximately population-based cohorts (i.e., did not select 
articipants on the basis of having previous disease) and excluded 
1 cohorts that recruited only young participants (e.g., birth co- 
orts), did not measure exposures/outcomes of interests, or could 
ot be accessed by the original investigators [27] . We accessed 2 3 cohorts from 13 countries (37% of LAC countries). From these 
3 cohorts, 5 included participants who attended a specific health 
entre [28-30] or were members of a professional organization 
uch as The Mexican Teachers’ Cohort [31] and the Health Workers 
ohort Study [32] . The other cohorts sampled individuals from the 
eneral population. Individual-level data from each cohort were 
eceived by the CC-LAC and were subsequently harmonised and 
ooled for the present analyses [27] . 
From the pooled 33 cohorts, we excluded two that did not as- 
ertain either fatal or non-fatal cardiovascular events; we further 
xcluded 18 cohorts that did not ascertain non-fatal cardiovascular 
vents from analysis of fatal- and non-fatal outcomes. Thus, our es- 
imates for fatal cardiovascular events were informed by 31 cohorts 
ith a mean follow-up of 8.8 years (standard deviation = 3.1), 
hile our estimates for fatal and non-fatal cardiovascular events 
ere informed by 13 cohorts with a mean follow-up of 8.5 years 
standard deviation = 5.3). 
We estimated incidence rate ratios which we will hereafter re- 
er to as relative risks (RRs) and 95% Confidence Intervals (95% CI) 
or each selected cardio-metabolic risk factor on fatal and non-fatal 
ardiovascular diseases. We used these RRs to estimate the propor- 
ion and number of deaths attributable to each risk factor. 
.1. Cardiovascular outcomes 
We analysed two outcomes separately: i) fatal and non-fatal 
ardiovascular events and ii) fatal cardiovascular events. Non-fatal 
ardiovascular events were not analysed alone because of the 
mall number of events in many age groups. Cardiovascular events 
ere identified using data from vital registration systems, clini- 
al records or verbal autopsies, and where relevant adjudicated by 
ach cohort (Supplementary Table 1). 
.2. Cardio-metabolic risk factors 
The risk factors of interest were systolic blood pressure (SBP, in 
mHg), body mass index (BMI, in kg/m 2 ), fasting plasma glucose 
FPG, in mmol/L), total serum cholesterol (in mmol/L) and non- 
igh-density lipoprotein cholesterol (non-HDL, in mmol/L). These 
ariables were collected following standardised protocols in each 
ohort. We only examined SBP as the relationship between SBP 
nd CVD outcomes is stronger than that of diastolic blood pressure 
 8 , 33 ]. 
.3. Statistical analysis 
.3.1. Handling of missing data 
BMI was missing in 12% of the pooled observations, while this 
umber for SBP, total cholesterol, FPG and non-HDL cholesterol 
anged from 66% to 80% (Supplementary Table 2). We used multi- 
le imputation and fitted the regression models in each of 50 im- 
uted datasets, pooling the estimates following Rubin’s rules [34] . 
n sensitivity analyses, we used a complete-case dataset, and we 
bserved minor differences for non-HDL cholesterol but overall the 
esults were unchanged using multiple imputation (Supplementary 
igure 1). Detailed methods on multiple imputation are available 
n Supplementary Material (pp. 7-8). The main results herein pre- 
ented are based on the multiple imputation data. 
.3.2. Adjusting for Regression Dilution Bias (RDB) 
As the selected risk factors have a natural variability during 
ollow-up, the estimated associations between baseline one-off
easures underestimate the effect of “usual” exposure. This is of- 
en referred to as regression dilution bias [ 35 , 36 ]. To adjust for this




















































































































ias, we used data from 10 of our cohorts with repeated risk fac- 
or measurements and used standard analytic methods (MacMahon 
ethod) [ 35 , 36 ] to calculate correction factors. The estimated cor- 
ection factors were: 1.10 for BMI, 1.50 for SBP, 1.53 for FPG, 1.75 
or total cholesterol, and 1.85 for non-HDL cholesterol. Further de- 
ails about the RDB methods are available in the expanded meth- 
ds (Supplementary Material pp. 6-7). 
.3.3. Survival analysis 
For each cardio-metabolic risk factor, we fitted a Poisson lin- 
ar mixed effects regression model for each age group separately 
35-44, 45-54, 55-64, 65-74, 75-84, 85 + years) in which the in- 
ependent variable was the risk factor, adjusted for sex and age 
t risk (i.e., at follow-up/event) within each age-group. A cohort- 
pecific random intercept was included as well as the natural log- 
rithm of the follow-up time as an offset. The coefficient of each 
isk factor from this model represents the log-incidence rate ratio 
or one-unit increase in the risk factor in each 10-year age group. 
e applied the RDB correction factor to these coefficients (in the 
og scale). For further details, refer to the extended methods (Sup- 
lementary Material pp. 5-11). 
To better understand any potential differences in RRs between 
ub-regions in LAC, we computed RDB-adjusted RRs for fatal car- 
iovascular diseases for Central America & the Caribbean (Costa 
ica, Cuba, Dominican Republic, Puerto Rico and Trinidad & To- 
ago) versus South America (Argentina, Brazil, Chile, Colombia, 
eru, Uruguay and Venezuela). We included Mexico in the former 
roup to preserve geographic proximity. To compare our results 
ith a previous analysis of cohort data pooling studies that re- 
orted RRs for fatal ischaemic heart disease and stroke subtypes 
eparately [5] , we weighted their estimated RRs by the relative 
revalence of these outcomes in LAC. 
.3.4. Quantifying the population-level impact of risk factors 
Following a comparative risk assessment approach [37] , we es- 
imated the population attributable fraction (PAF) for each risk fac- 
or on cardiovascular deaths in 35 countries of the region com- 
aring the current mortality burden to the one that would have 
een observed if the mean levels in the population were optimal 
Supplementary Material p. 9). The optimal levels in the population 
ere derived from previous analyses of global burden of disease 
5] . Current mean levels of BMI, SBP, total cholesterol and non-HDL 
holesterol for each country and by five-year age group and sex, 
ere extracted from the NCD-RisC ( http://ncdrisc.org/ ) [ 15 , 22 , 23 ].
his information was not available for FPG, therefore, we did not 
nclude non-optimal glucose in these analyses. The number of car- 
iovascular deaths for the year 2019 was extracted from the esti- 
ates provided in the Global Burden of Disease (GBD) Study [38] . 
e used the RRs herein estimated (10-year age groups), and we 
nterpolated them into 5-year age groups (Supplementary Figure 
 and Supplementary Table 7) [5] . We used the same age-specific 
Rs for men and women across countries in LAC, as we found no 
vidence of different RRs by sex. We estimated crude attributable 
eath rates per 10 0,0 0 0 person-years by multiplying PAFs by total 
VD deaths and dividing by the adult population of each coun- 
ry, which was also extracted from the GBD Study. Further de- 
ails about the comparative risk assessment are available in the 
xpanded methods (Supplementary Material pp. 8-9). Countries for 
hich we made estimates are those in common between the GBD 
tudy and the NCD-RisC (35 countries and territories in LAC). 
.4. Risk of bias in each study 
We evaluated three sources of bias. First, selection bias due to 
nrolment of participants. The risk of selection bias in these co- 
orts is rather small because inclusion in the study is unlikely to 3 e simultaneously related to exposure and outcome. Second, mea- 
urement bias. As explained above and in Supplementary Mate- 
ial p. 04, major variables of interest were measured except for 
MI which was self-reported in one cohort [ 31 , 39 ]. These variables
re commonly measured in cardiovascular cohorts and were mea- 
ured following standard procedures. Regarding the outcomes, we 
id not pool cohorts in which this information was not verified 
sing links to vital registration data or adjudication (Flow Diagram 
n Supplementary Material p. 04). Third, confounding. We adjusted 
or age, sex and cohort in all analyses as we were interested in 
omparing the magnitude of our RRs with those of other global 
ooling studies which used the same set of potential confounders 
5] . 
.4.1. Role of the funding source 
The funder of the study had no role in study design, data col- 
ation, analysis, interpretation, or writing of the report. RMC-L and 
D had full access to the data in the study. RMC-L and GD had 
nal responsibility for the decision to submit for publication. 
. Results 
In the group of cohorts analysed for fatal outcomes, women 
ere younger than men (46.1 vs 55.7 years), while in the sec- 
nd set of cohorts the age was more alike (52.7 vs 52.1 years). 
n both sets of cohorts (i.e., analysis for fatal as well as for fatal 
nd non-fatal outcomes), women had higher BMI than men (27.4 
g/m 2 vs 26.2 kg/m 2 and 28.6 kg/m 2 vs 26.4 kg/m 2 ); mean total 
holesterol was also higher in women (5.4 mmol/L vs 5.2 mmol/L 
nd 5.3 mmol/L vs 5.2 mmol/L). The average non-HDL cholesterol 
as slightly higher among men than women in both sets of co- 
orts (4.1 mmol/L vs 4.2 mmol/L and 4.1 mmol/L vs 4.2 mmol/L). 
n both sets of cohorts, mean SBP was higher among men than 
omen (131 mmHg vs 134 mmHg and 128 mmHg vs 133 mmHg; 
upplementary Table 3B). 
For fatal outcomes, the 31 selected cohort studies contributed 
ith 168,287 eligible participants aged 20 years old and over. More 
han four fifths were women (83.7%) and they were on average 
7.7 (standard deviation (SD) = 12.2) years old at baseline. The 
ean BMI was 27.2 kg/m 2 (SD = 4.8), the average SBP was 131 
mHg (SD = 22.1), the mean FPG was 5.5 mmol/L (SD = 1.9), the 
ean total cholesterol was 5.3 mmol/L (SD = 1.3), and the average 
on-HDL cholesterol was 4.2 mmol/L (SD = 1.3) (Supplementary 
able 3). The mean follow-up was 8.9 (SD = 3.1) years. In the 31 
ohorts analysed for fatal outcomes we observed, 1,710 events (116 
95% CI: 111-122) per 10 0,0 0 0 person-years). 
We observed an age gradient in the magnitude of the RDB- 
djusted RRs across all cardio-metabolic risk factors for fatal car- 
iovascular outcomes, with smaller RRs in older ages; this pat- 
ern was less clear for total cholesterol and non-HDL cholesterol 
 Figure 1 , Supplementary Table 5). The magnitude of the RRs in 
he youngest group (35-44) was at or above 1.3 ( Figure 1 , Supple-
entary Table 5), with the largest estimate for SBP on fatal cardio- 
ascular events (RR = 1.9, 95% CI: 1.4-2.4); conversely, the RRs for 
PG in the youngest age group was 1.3 (95% CI: 0.9-1.9) ( Figure 1 ,
upplementary Table 5). 
In regional sub-group analyses, we did not observe substantial 
ifferences in the magnitude of the RRs for fatal outcomes. In both 
ub-regions, we could not observe a clear age gradient with larger 
Rs in younger groups; except for SBP where there was an age gra- 
ient from age 45 years ( Figure 2 , Supplementary Table 6). 
For fatal and non-fatal outcomes, the 13 cohorts contributed 
ith 27,554 eligible individuals. Almost two thirds were men 
64.1%), and the mean age was 52.3 (10.5) years. The mean BMI, 
BP, FPG and total cholesterol and non-HDL cholesterol was: 27.2 
g/m 2 (SD = 5.1), 131 mmHg (SD = 21.0), 5.3 mmol/L (SD = 1.7), 
The Lancet Regional Health - Americas 4 (2021) 10 0 068 














































Figure 1. Age-specific relative risks for fatal and fatal plus non-fatal cardiovascular disease associated with usual levels of selected cardio-metabolic risk factors. While the 
upper panel shows estimates without accounting for regression dilution bias, the lower panel shows estimates accounting for regression dilution bias; all estimates were 
adjusted by sex and age (within each age group). Age groups based on age at risk. Estimates for fatal plus non-fatal events included only the first five age groups (insufficient 
observations in the eldest age group). RR: relative risk; 95% CI: 95% confidence interval; BMI: body mass index; SBP: systolic blood pressure. The red vertical line at relative 
risk = 1.5 and the orange vertical line at relative risk = 2.0 on the X-axis. 
SBP (10 mmHg) BMI (5 kg/m^2) Glucose (1 mmol/L) Total Cholesterol (1 mmol/L) Non−HDL Cholesterol (1 mmol/L)


















Figure 2. Age-specific relative risks for fatal cardiovascular disease associated with usual levels of selected cardio-metabolic risk factors by sub-regions. All models were 
adjusted by sex and age (within each age group). Age groups based on age at risk (i.e. at outcome). RR: relative risk; 95% CI: 95% confidence interval; BMI: body mass index; 
SBP: systolic blood pressure. Only results adjusted for regression dilution bias are presented. Results as per multiple imputation. Insufficient observations to reliably compute 
































.3 mmol/L (SD = 1.1) and 4.1 mmol/L (SD = 1.1), respectively 
Supplementary Table 3). The mean follow-up was 8.5 (SD = 5.3) 
ears. In the 13 cohorts analysed for fatal and non-fatal events, 
here were 577 non-fatal events (246 (95% CI: 227-267) per 
0 0,0 0 0 person-years) and 677 fatal events (288 (95% CI: 267-311) 
er 10 0,0 0 0 person-years). 
We observed an age gradient in the magnitude of the RDB- 
djusted RRs across all cardio-metabolic risk factors for fatal and 
on-fatal cardiovascular outcomes, with smaller RRs in older ages 
 Figure 1 , Supplementary Table 5). The magnitude of the RRs in 
he youngest group (35-44) was at or above 1.2 ( Figure 1 , Supple-
entary Table 5). In the youngest age group, the largest RR for 
atal and non-fatal cardiovascular outcomes was observed for SBP 
RR = 1.7, 95% CI: 1.2-2.4); conversely, the smallest RR was for FPG 
RR = 1.2, 95% CI: 0.8-1.9) ( Figure 1 , Supplementary Table 5). 
The age-specific RRs for fatal and non-fatal CVD for SBP and 
PG were remarkably similar to those reported from cohorts 4 ostly conducted in high-income countries ( Figure 3 ) [5] . For TC, 
ur RRs appeared to be smaller for the two youngest age groups, 
hough these differences were statistically insignificant ( Figure 3 ). 
or BMI, the RRs were consistently smaller in magnitude for par- 
icipants younger than 75 years old, with the largest difference for 
hose in the age group 55-64 years ( Figure 3 ): 1.24 (95% CI: 1.11-
.38) vs. 1.50 (95% CI: 1.41-1.61). 
Non-optimal SBP was responsible for the largest proportion of 
ttributable cardiovascular deaths across countries, with a pro- 
ortional effect ranging from 30.7% among Cuban women to 
8.0% among men from Grenada. The second largest proportion 
or attributable CVD mortality was due to non-optimal non-HDL 
holesterol, which proportional effect varied between 13.9% (Chile, 
omen) and 31.2% (Guyana, women). The proportional effect of 
on-optimal BMI and total cholesterol were smaller. For BMI the 
roportional effect ranged from 6.1% in women from Cuba to 19.6% 
n men from Saint Kitts and Nevis, whereas for total cholesterol 
The Lancet Regional Health - Americas 4 (2021) 10 0 068 
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Figure 3. Relative risks from the pooled analysis of PSC and APCSC [5] compared with those from LAC cohort pooling. Estimates from LAC cohorts are those adjusted by 
regression dilution bias and based on multiple imputation for fatal and non-fatal cardiovascular outcomes. Our estimates for fatal plus non-fatal outcomes were computed 
for the first five age groups only (insufficient observations in the oldest age group). PSC: Prospective Studies Collaboration; APCSC: Asia Pacific Cohort Studies Collaboration. 

























Figure 4. Population attributable fraction (PAF, %) in women compared to men by risk factor and sub-regions. BMI: body mass index; SBP: systolic blood pressure. 
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Crude attributable death rate per 100,000 person−years
Figure 5. Crude attributable death rates per 10 0,0 0 0 person-years by risk factors, sub-regions and sex. Results at the sub-region level are mean averaged accounting for the 
population size of the countries within each sub-region. BMI: body mass index; SBP: systolic blood pressure; TC: total cholesterol. The vertical lines along the numbers at 



























































hese numbers were 4.4% (Guatemala, men) and 18.1% (Guyana, 
omen; Supplementary Figure 3). 
The proportional effect of non-optimal total cholesterol tended 
o be larger among women than among men, as was observed in 
4 countries ( Figure 4 ); the largest absolute difference between 
omen and men was observed in Guatemala (11.6% in women vs 
.4% in men; Supplementary Figure 3). On the other hand, the pro- 
ortional effect of non-optimal SBP was higher among men than 
mong women in most countries ( Figure 4 ), with the largest differ- 
nce in Uruguay (47.5% in men vs 35.4% in women; Supplementary 
igure 3). 
Over half a million deaths (502,913 (95% credible inter- 
al = 340,637-653,242) out of a total of 1,094,795 CVD deaths 
n LAC) were attributable to non-optimal SBP in 2019. The sec- 
nd largest effect was estimated for non-optimal non-HDL choles- 
erol at 224,118 (95% credible interval = 83,755-388,176) deaths 
nd the lowest for non-optimal BMI at 119,498 (95% credible inter- 
al = 61,201-200,824) ( Table 1 ). Brazil, Mexico and Argentina, in 
hat order, had the largest numbers of attributable deaths across 
he four risk factors for both women and men; Colombia displaced 
rgentina from the third place regarding non-HDL cholesterol in 
omen (Supplementary Figure 3). 
Most of the cardiovascular disease deaths attributable to non- 
ptimal BMI were premature ( < 70 years of age; Table 1 ), ranging
rom 72% among women in Southern and Tropical Latin America, 
o 83% among men in the Caribbean ( Table 1 ). On the other ex-
reme, the 44% of all cardiovascular disease deaths attributable to 
on-optimal SBP was premature; this ranged from 31% (women in 
ndean Latin America) to 54% (men in Southern and Tropical Latin 
merica; Table 1 ). 
Across the four sub-regions, the crude attributable death rate 
er 10 0,0 0 0 person-years due to non-optimal risk factors was con- 
istently larger among men for BMI, SBP and non-HDL cholesterol 
 Figure 5 ). Consistently across all sub-regions, non-optimal SBP was 6 esponsible for the largest number of attributable deaths for both 
en and women. Similarly, non-optimal non-HDL cholesterol al- 
ays ranked second ( Figure 5 ). 
For men, country-specific attributable death rates to non- 
ptimal SBP ( Figure 6 A, Supplementary Figure 3), was the small- 
st in Peru (54 per 10 0,0 0 0 person-years) and Guatemala (67), and 
he largest in Dominica (249) and Guyana (282). For non-optimal 
on-HDL cholesterol, we observed the smallest attributable death 
ates in Guatemala (25) and Peru (27), and the largest in Domini- 
an Republic (107) and Guyana (158). Finally, for BMI, the lowest 
ttributable death rates were observed in Peru (13) and Guatemala 
14), and the largest in Saint Lucia (64) and Saint Kitts and Nevis 
75). 
For women ( Figure 6 B, Supplementary Figure 3), the small- 
st attributable death rate to non-optimal SBP was estimated in 
eru (38 per 10 0,0 0 0 person-years) and Guatemala (64), while 
uyana (228) and Dominica (261) had the largest rates. For non- 
DL cholesterol, the lowest attributable rates were observed in 
eru (21) and Chile (30), while the largest rates were in Haiti (109) 
nd Guyana (142). For non-optimal BMI, the lowest attributable 
eath rates were observed in Peru (10) and Panama (14), whilst 
he largest rates were in Saint Kitts and Nevis (51) and Guyana 
76). 
. Discussion 
Benefiting from a unique database of pooled individual-level 
ata from 31 cohort studies in 13 LAC countries [27] , we estimated 
ge-specific RRs for major cardiovascular disease risk factors. We 
bserved smaller RRs for BMI compared with those used in the 
lobal estimates of disease burden based on cohort collaborations 
riginating mostly in high-income countries. We observed an age 


































Number of cardiovascular deaths in 2019 attributable to each risk factor by sub-region and sex in Latin America and the Caribbean 
Region Sex 
BMI SBP TC Non-HDL 
Estimate Lower CI Upper CI Estimate Lower CI Upper CI Estimate Lower CI Upper CI Estimate Lower CI Upper CI 
All ages (ages 20 and above) 
Andean Latin America Men 3299 1605 5687 13590 8107 18597 3118 562 7135 6841 2548 11916 
Andean Latin America Women 3124 1602 5450 11216 5757 16342 3532 622 8193 6189 2025 11376 
Caribbean Men 6176 2832 10630 27503 16887 36885 6178 1123 13847 12863 5229 21835 
Caribbean Women 5134 2312 9475 24135 12787 34567 7710 1593 17115 13125 4588 23590 
Central Latin America Men 21147 11158 34447 81481 53892 107084 16548 3844 35438 39095 15439 65842 
Central Latin America Women 16734 8649 28854 67962 40603 93829 20079 4416 43640 35646 11593 64701 
Southern and Tropical Latin America Men 36418 19372 58019 155845 121477 187436 30617 9504 58140 61208 25953 99449 
Southern and Tropical Latin America Women 27466 13672 48261 121181 81127 158501 32048 7881 66512 49151 16381 89467 
Premature (below age 70) 
Andean Latin America Men 2659 1494 3920 6072 3905 7854 1851 473 3519 3886 2003 5631 
Andean Latin America Women 2390 1474 3335 3466 1848 4883 1580 495 2855 2813 1490 4051 
Caribbean Men 5136 2651 7880 14327 9244 18297 3828 930 7373 7824 4119 11345 
Caribbean Women 3932 2104 5920 9617 5259 13180 3697 1248 6596 6342 3397 9102 
Central Latin America Men 17209 10396 24328 40272 28791 49875 10278 3269 18462 22925 12156 32755 
Central Latin America Women 12342 7816 16888 21806 14077 28469 8553 3340 14340 15098 8294 21297 
Southern and Tropical Latin America Men 29324 17847 41325 83297 69701 94929 19949 7806 33399 38343 20426 54830 
Southern and Tropical Latin America Women 19765 12201 27444 41732 31403 50817 14050 5875 22882 22272 11925 31983 
Premature-to-all-ages ratio (%) 
Andean Latin America Men 80.60 93.13 68.92 44.68 48.16 42.23 59.37 84.25 49.33 56.81 78.60 47.26 
Andean Latin America Women 76.52 92.02 61.19 30.91 32.10 29.88 44.74 79.54 34.85 45.45 73.56 35.61 
Caribbean Men 83.16 93.61 74.13 52.09 54.74 49.61 61.97 82.80 53.24 60.82 78.78 51.96 
Caribbean Women 76.59 90.99 62.47 39.85 41.12 38.13 47.95 78.35 38.54 48.32 74.04 38.59 
Central Latin America Men 81.38 93.17 70.62 49.42 53.42 46.58 62.11 85.04 52.10 58.64 78.74 49.75 
Central Latin America Women 73.75 90.36 58.53 32.09 34.67 30.34 42.60 75.62 32.86 42.35 71.54 32.92 
Southern and Tropical Latin America Men 80.52 92.13 71.23 53.45 57.38 50.65 65.16 82.14 57.45 62.64 78.71 55.13 
Southern and Tropical Latin America Women 71.96 89.25 56.86 34.44 38.71 32.06 43.84 74.54 34.40 45.31 72.80 35.75 
BMI: body mass index; SBP: systolic blood pressure; TC: total cholesterol; Non-HDL: non-HDL cholesterol; CI: 95% credible interval. All ages included observations aged ≥20 years, whereas premature refers to 
ages between 20 and 69 years. The premature-to-all-ages ratio quantifies the ratio of the estimated attributable deaths below age 70 to the corresponding estimate for all ages expressed as a percentage. 
7
 




















































Figure 6. Crude attributable death rates per 10 0,0 0 0 person-years by risk factor and country in Latin America and the Caribbean in men (A) and women (B). Countries are 
clustered within sub-regions (Andean Latin America, the Caribbean, Central Latin America as well as Southern Latin America). Colour scale allows comparison within each 




















































iduals. Our results suggested that the RRs did not differ between 
entral America & the Caribbean sub-region compared with South 
merica. The largest attributable CVD deaths across the selected 
isk factors were due to non-optimal SBP, followed by non-HDL 
holesterol. These risk factors had a much larger impact on cardio- 
ascular deaths in the Caribbean and Southern and Tropical sub- 
egions. 
The age gradient of the estimated RRs in our analysis is 
onsistent with prior pooled analysis of large cohort studies 
 2 , 5 , 9 , 10 , 13 , 40 ]. The magnitude of age-specific RRs was similar in
ur analyses compared with prior pooling projects of cohorts in 
igh-income countries and those of the Asia-Pacific region [5] ; 
owever, for BMI, our estimated RRs were smaller for many age 
roups below the age of 75, particularly for people aged 55-64. The 
eported RRs for BMI from the Prospective Studies Collaboration, 
nd the Asia Pacific Cohort Studies Collaboration did not account 
or RDB [ 10 , 41 ]. Adjusting for RDB, would have led to even higher
Rs compared with ours. Such similarity may reflect the same un- 
erlying biology of these risk factors and lack of major modifica- 
ions by lifestyle or environmental risk factors that do differ across 
egions. In fact, where patterns or lengths of exposure matter as 
t is the case for smoking and alcohol use, RRs of cardiovascular 
utcomes differ substantially by region [25] . In contrast, the ob- 
erved differences in RRs for BMI may be explained by the shorter 
uration of the weight gain in the LAC region compared with high- 
ncome countries. That is, high-income populations have been ex- 
osed to non-optimal BMI levels longer than most populations 8 n LAC [22] , and are therefore experiencing the larger cumulative 
armful effects of BMI on cardiovascular health. Alternatively, the 
ame level of BMI may correspond to a healthier body fat distribu- 
ion in LAC compared with high-income populations. The current 
vidence on such a difference in fat distribution at the same level 
f BMI is mixed [ 42 , 43 ] and further research is needed using larger
opulation-based surveys with measurements of body composition 
n LAC. Our RRs for non-HDL cholesterol are consistent with a re- 
ent analysis of the PURE study, which did not find substantial dif- 
erences in RRs for non-HDL cholesterol between high-, middle- 
nd low-income countries [4] . 
The observed differences in RRs for BMI may explain the differ- 
nces in our estimates of attributable deaths to cardio-metabolic 
isk factors in LAC versus those reported by the GBD Study, which 
ses RRs mostly informed by epidemiological studies in high- 
ncome countries. For example, we estimated a crude attributable 
eath rate for non-optimal BMI in women in Peru of 10 per 
0 0,0 0 0, compared with 18 cardiovascular disease deaths reported 
y the GBD Study [44] for Guyana we estimated 76 compared to 86 
44] . Notably, the GBD Study risk estimates include other cardio- 
ascular outcomes besides those herein analysed- partly explaining 
he differences. 
Our results show that non-optimal SBP was responsible for the 
argest number of cardiovascular disease deaths, followed by non- 
DL cholesterol, total cholesterol and BMI. This ranking is simi- 
ar to the one proposed by the GBD Study in 2019, in which SBP 
anked first, followed by LDL-Cholesterol, fasting plasma glucose 















































































































nd BMI [45] . This suggests that the ranking based on global risk 
stimates still apply to LAC, yet the burden attributable to each risk 
actor may be different. That difference, as herein proposed, may 
e overestimating the cardiovascular disease mortality attributable 
o non-optimal BMI in LAC. 
Arguably, LAC-based risk estimates -particularly for BMI- pro- 
ide more valid metrics for countries in LAC to quantify the bur- 
en of key cardio-metabolic risk factors. This evidence could al- 
ow prioritizing the risk factor(s) with the largest burden, develop 
olicies and interventions to address these priorities, and set up 
urveillance systems to monitor the progress towards international 
nd local goals. Our results could be taken as parameters upon 
hich goals can be set to reduce cardiovascular burden in LAC 
nd in each country in the region given that metrics to mea- 
ure the progress and surveillance of cardiovascular diseases were 
ostly informed by countries outside LAC. Considering the sharp 
ise in obesity and diabetes in the region [15] , despite our evidence 
hat shows lower RRs compared with high-income countries, over- 
eight/obesity remains one of the highest-ranking risk factors for 
VD; obesity control and prevention policies should continue to 
emain top priorities. 
Our work has several strengths. The risk estimates are age- 
pecific and were computed following consistent methods using 
he largest pooled database of cohorts in LAC. We analysed data 
rom 13 countries including at least one from each sub-region in 
AC, a work never conducted before. Analysing individual level 
ata, in contrast to published estimates [ 18 , 46 ], allowed us to ex-
mine interactions between different variables. The RRs were ad- 
usted for regression dilution bias using LAC data providing the RR 
f “usual” exposure to risk factors. We used multiple imputation 9 o handle missing data for risk factors at baseline. Nevertheless, 
e acknowledge several limitations. Due to data availability, we 
ould not study other risk factors such as LDL-cholesterol. Likewise, 
ome outcomes were not available, preventing us from disentan- 
ling, for example, ischaemic from haemorrhagic stroke. We were 
lso unable to examine RRs in all sub-regions (e.g., Andean Latin 
merica and southern Latin America) due to the small numbers 
f events. We therefore only explored risk estimates from South 
merica with those from Central America and the Caribbean, and 
ven in this case, confidence intervals were wide, particularly in 
he youngest and oldest age groups. Many cohorts did not col- 
ect data on non-fatal events (possibly due to the younger age of 
articipants or complexities and costs of identifying and adjudi- 
ating non-fatal events), precluding a separate analysis. The lim- 
ted number of non-fatal events could have also affected the main 
esults (RRs for both fatal and non-fatal CVD), as these estimates 
ould have been mostly driven by fatal events; however, results 
or fatal outcomes only showed the same age pattern and the RRs 
ad a similar magnitude as those including both fatal and non- 
atal events. Mortality risk may also be confounded by health care 
ccess and control of non-communicable diseases, variables that 
ere not included in the regression models. A few variables had 
 large proportion of missing values across cohorts mostly because 
 subset of cohorts did not include these measurements in their 
rotocol, as opposed to non-response or missing measurements 
ithin each cohort. We used modelled estimates of CVD deaths 
y country, age and sex from the GBD 2019 Study to calculate the 
ttributable number of deaths which makes our results compara- 
le and consistent across countries [38] . However, the estimated 
VD mortality may be biased in countries especially if local data is 






















































































































ot incorporated in the GBD analyses and/or if modelling assump- 
ions are not valid for a particular region/sub-region. Also in rela- 
ion to the GBD Study, we acknowledge that GBD deliver estimates 
or several years whereas we only used their most recent estimates 
2019); we focused on the most recent year because we aimed to 
rovide estimates to inform policies and goal setting, rather than 
howing time patterns. Cohorts herein analysed for fatal outcomes 
ncluded more women than men; interpretation of these estimates 
hould be made in light of this profile. We only presented results 
t the country level. Future work should also study cardiovascular 
isease burden at the subnational level, ideally in all countries in 
AC considering its substantial geographical and socioeconomic di- 
ersity. We encourage researchers in LAC to use the risk estimates 
erein reported to conduct subnational analysis of cardiovascular 
isease burden. We pooled multiple cohorts which included a ran- 
om sample of the general population or studied specific groups 
e.g., The Mexican Teachers’ Cohort). We studied cardio-metabolic 
isk factors (e.g., blood pressure and total cholesterol) which were 
ollected following objective, standard and comparable methods 
etween cohorts. The risk of selection bias is quite low because 
he probability of being selected in these studies is unlikely to 
e simultaneously related to the exposure and outcome. Regarding 
MI, except for one cohort we used measured weight and height 
hich reduces measurement error; this is method is consistent 
ith other cohort pooling projects. 
In conclusion, using data from the first pooling project of cohort 
tudies in LAC we found that RRs of cardiovascular disease per unit 
ncrease in blood pressure, glucose and cholesterol are remark- 
bly similar to previous pooling projects that used data mostly 
rom high-income countries. In contrast, we observed smaller age- 
pecific RRs for BMI. The estimated RRs offer region-specific evi- 
ence that can be used to update estimates of attributable burden 
f disease to better inform regional policies and goals. One of the 
trategic lines of action in Pan American Health Organization’s Plan 
f Action for the Prevention and Control of Non-communicable 
iseases in the Americas 2013-2019, was to strengthen country ca- 
acity for surveillance on non-communicable diseases and their 
isk factors [47] . Our results can help improve the validity of 
uch surveillance effort s by emphasizing the use of local data 
nd evidence in prioritizing and implementing CVD prevention 
rograms. 
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